CUBIST PHARMACEUTICALS

Health Issues

Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care & Education Reconciliation Act of 2010 (Pub. L. 111-152), Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144), S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013, S. 959, Pharmaceutical Compounding Quality and Accountability Act,H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act, Health care reform implementation; the 340B program of the Health Resources & Services Administration (HRSA), specifically 340B drug pricing issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities. Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints; antibiotic resistance among elderly population; issues related to 340B Drug Pricing Program; reimbursement issues for antibiotics.

TargetedSENATE · HOUSE OF REPRESENTATIVES

Medicare/Medicaid

Issues related to Medicare reimbursement of antibiotics; S. 2000 / H.R. 4015, The SGR Repeal & Medicare Provider Payment Modernization Act of 2014; H.R. 4302, Protecting Access to Medicare Act of 2014 and Public Law No. 113-93, and potential Medicare offsets that might be applied to prescription drugs in all issues listed.

SENATE · HOUSE OF REPRESENTATIVES